The investigators hypothesis is that oral Sensoril® (as compared to placebo) will enhance
cognitive abilities (specifically measures of attention, executive function, working memory,
and visuospatial ability) in persons with bipolar disorder. Secondarily, the investigators
hypothesize there will be secondary improvements in residual mood/anxiety symptoms, and
metabolic indices, if impaired (fasting blood glucose and lipids).
The investigators aim to test these hypotheses by conducting a randomized, placebo
controlled, add on treatment trial of Sensoril® (added to existing mood stabilizer treatment)
recruiting 60 subjects with DSM IV-TR bipolar disorder for a period of 8 weeks. Measures of
cognition, psychopathology and laboratory indices will be utilized for evaluating primary and
secondary outcomes, along with safety assessments.
Phase:
Phase 3
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
National Alliance for Research on Schizophrenia and Depression